Molecular characterization of *Plasmodium falciparum* antifolate resistance markers in Thailand between 2008 and 2016

Rungniran Sugaram1,2, Kanokon Suwannasin3, Chanon Kunasol3, Vivek Bhakta Mathema3, Nicholas P. J. Day2,4, Prayuth Sudathip2, Preecha Prempree2, Arjen M. Dondorp2,4 and Mallika Imwong1*

Abstract

**Background:** Resistance to anti-malarials is a major threat to the control and elimination of malaria. Sulfadoxine–pyrimethamine (SP) anti-malarial treatment was used as a national policy for treatment of uncomplicated falciparum malaria in Thailand from 1973 to 1990. In order to determine whether withdrawal of this antifolate drug has led to restoration of SP sensitivity, the prevalence of genetic markers of SP resistance was assessed in historical Thai samples.

**Methods:** *Plasmodium falciparum* DNA was collected from the Thailand–Myanmar, Thailand–Malaysia and Thailand–Cambodia borders during 2008–2016 (N = 233). Semi-nested PCR and nucleotide sequencing were used to assess mutations in *Plasmodium falciparum* dihydrofolate reductase (pfdhfr), *P. falciparum* dihydropteroate synthase (pfdhps). Gene amplification of *Plasmodium falciparum* GTP cyclohydrolase-1 (pfgch1) was assessed by quantitative real-time PCR. The association between pfdhfr–pfdhps mutations and pfgch1 copy numbers were evaluated.

**Results:** Mutations in pfdhfr/pfdhps and pfgch1 copy number fluctuated overtime through the study period. Altogether, 14 unique pfdhfr–pfdhps haplotypes collectively containing quadruple to octuple mutations were identified. High variation in pfdhfr–pfdhps haplotypes and a high proportion of pfgch1 multiple copy number (51% (73/146)) were observed on the Thailand–Myanmar border compared to other parts of Thailand. Overall, the prevalence of septuple mutations was observed for pfdhfr–pfdhps haplotypes. In particular, the prevalence of pfdhfr–pfdhps, septuple mutation was observed in the Thailand–Myanmar (50%, 73/146) and Thailand–Cambodia (65%, 26/40) border. In Thailand–Malaysia border, majority of the pfdhfr–pfdhps haplotypes transaction from quadruple (90%, 9/10) to quintuple (65%, 24/37) during 2008–2016. Within the pfdhfr–pfdhps haplotypes, during 2008–2013 the pfdhps A/S436F mutation was observed only in Thailand–Myanmar border (9%, 10/107), while it was not identified later. In general, significant correlation was observed between the prevalence of pfdhfr1164L (φ = 0.213, p-value = 0.001) or pfdhps K540E/N (φ = 0.399, p-value ≤ 0.001) mutations and pfgch1 gene amplification.

**Conclusions:** Despite withdrawal of SP as anti-malarial treatment for 17 years, the border regions of Thailand continue to display high prevalence of antifolate and anti-sulfonamide resistance markers in falciparum malaria. Significant association between pfgch1 amplification and pfdhfr (I164L) or pfdhps (KS40E) resistance markers were observed, suggesting a compensatory mutation.

**Keywords:** pfdhfr, pfdhps, pfgch1, Sulphadoxine–pyrimethamine

*Correspondence: noi@tropmedres.ac
1 Department of Molecular Tropical Medicine and Genetics, Faculty of Tropical Medicine, Mahidol University, 420/6 Rajvithi Rd., Bangkok 10400, Thailand
Full list of author information is available at the end of the article

© The Author(s) 2020. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Background

Both falciparum and vivax malaria remains an important public health problem in border regions of Thailand. Resistance to anti-malarials presents a major hurdle for eradication of the disease [1]. Drug resistance in both Plasmodium falciparum and Plasmodium vivax has been reported as early as the 1950s [2]. Sulfadoxine–pyrimethamine (SP), a folate pathway inhibitor was deployed in Thailand for the treatment of uncomplicated falciparum malaria from 1973 until 1991 [3]. By 1991, substantial loss of the SP drug efficacy prompted a change in first-line treatment in Thailand [3]. Molecular investigations revealed that mutations in P. falciparum dihydrofolate reductase (pfdhfr) and P. falciparum dihydropyrimidinase synthase (pfdhps) were associated with SP treatment failures and could be used as molecular markers for SP resistance [4, 5]. The mutations in pfdhfr and pfdhps often occurred in a step-wise progressive manner resulting in increased levels of drug resistance [4, 6]. Resistance to antifolates has also been linked to gene amplification of P. falciparum guanosine triphosphate cyclohydrolase 1 (pfgch1)-an enzyme responsible for coding a crucial enzyme in the folate pathway [7]. Parasites with pfgch1 amplification were reportedly less susceptible to antifolates as elevated expression of enzymes assisted antifolate resistance by competing with the drugs [7], and compensating the loss of fitness caused by mutations in pfdhfr and pfdhps by increasing the flux of metabolic products in the folate pathway [8]. An earlier study from Thailand reported a high proportion of parasites carrying multiple copies of pfgch1 and suggested an association between pfgch1 copy number variation (CNV) and the pfdhfr (I164L) mutations [8]. Several studies conducted between 1995 and 2008 have identified varying levels of triple or quadruple mutations in pfdhfr and pfdhps [5, 8, 9]. A more recent survey conducted in Ubonratchathani province close the Thailand–Cambodia borders, which had a lot of reports in many anti-malarial drug resistances [2, 3], showed high levels of pfdhfr (N51I, C59R, and S108N, ≥ 76%) and pfdhps (A437G, K540E, A581G or A437G, K540N, A581G or S436A, A437G, K540E, ≥ 90%) triple mutations [10]. These border areas are malaria endemic regions. Each site is geographically distant from other and often experiences high migration of diverse human population. However, data on the current status of antifolate and anti-sulfonamide resistance markers in P. falciparum in other major border regions of Thailand is scarce. Presumably, the persistence of highly mutations on SP-resistant markers related to the using of other drugs that may also induced pressure on pfdhfr and pfdhps of malaria parasite. The trimethoprim–sulfamethoxazole, which is used to treat acute respiratory infections, presented cross-resistance with pyrimethamine and sulfadoxine [11, 12]. Reemergence of chloroquine-sensitive P. falciparum in Malawi after a decade-long cessation of drug use shows that for some anti-malarials restoration of drug sensitivity is possible after removal of the drug pressure [13]. However, several factors including drug target, nature of genes and host/parasite genetic background may differently affect the persistence of SP resistance after removal of SP use.

The present study is a retrospective molecular surveillance of three antifolate and anti-sulfonamide resistance markers in samples obtained from the malaria endemic border provinces of Thailand between 2008 and 2016. It aimed at describing the current status of resistance markers after long-term cessation of SP as an anti-malarial treatment in Thailand.

Methods

Study sites and samples collection

Between 2008 and 2016, dried blood spots samples were collected using Whatman 3MM CHR filter paper from P. falciparum malaria patients in nine provinces bordering Thailand (Maehongson N=24; Tak N=16; Kanchanaburi N=70; Ranong N=34; Suratthani N=2; Ubonratchathani N=9; Sisaket N=19; Trat N=12; and Yala N=47 (Additional file 1: Table S3). All samples were acquired during anti-malarial drug therapeutic efficacy monitoring projects that were approved by the Research Ethics Committee of the Department of Disease Control, Ministry of Public Health, and Faculty of Tropical Medicine, Mahidol University, Thailand. DNA was extracted using QIAamp DNA Mini Kit (QIAGEN, Germany) and stored at 4 °C before analysis.

Pfdhfr and pfdhps sequencing and quality control

The pfdhfr and pfdhps genes were amplified using semi-nested PCR as described previously [14–17] (Additional file 1: Table S1). Amplified final products were sequenced using Whatman 3MM CHR filter paper from P. falciparum malaria patients in nine provinces bordering Thailand (Maehongson N=24; Tak N=16; Kanchanaburi N=70; Ranong N=34; Suratthani N=2; Ubonratchathani N=9; Sisaket N=19; Trat N=12; and Yala N=47 (Additional file 1: Table S3). All samples were acquired during anti-malarial drug therapeutic efficacy monitoring projects that were approved by the Research Ethics Committee of the Department of Disease Control, Ministry of Public Health, and Faculty of Tropical Medicine, Mahidol University, Thailand. DNA was extracted using QIAamp DNA Mini Kit (QIAGEN, Germany) and stored at 4 °C before analysis.

Plasmodium falciparum gch1 copy number estimation

To assess pfgch1 amplification, quantitative real-time PCR (qPCR) of the pfgch1 gene was compared with a
single copy reference gene (*seryl tRNA ligase*) (Accession No: A0A0L1I323). The specific probes and primers used have been described previously [8] (Additional file 1: Table S1). A laboratory *pfghc1* single copy strain and *pfghc1* multiple copies strain of *P. falciparum* were used as reference standard. The copy number of *pfghc1* gene was analysed from the threshold cycle (Ct) and ΔΔCt values calculated as follows: ΔΔCt = (Ct of *pfghc1* − Ct of *pfSerRs*) of sample − (Ct of *pfghc1* − Ct of *pfSerRs*) of Calibrator. The copy number of *pfghc1* were subsequently calculated using $2^{-\Delta Ct}$ method [18]. The *pfghc1* amplification cut off value was set at 1.5 copies number.

**Statistical analysis**

The *pfdhfr/pfdhps* mutations and *pfghc1* copy numbers were described as the proportion of each haplotype present at each border region. The changing trend of antifolate resistance markers after drug withdrawal was analysed by comparing the prevalence of markers over time by year. Chi-square ($\chi^2$) and the non-parametric phi correlation coefficient statistics ($\phi$) was used to evaluate the difference in frequency and associations respectively among the group of each antifolate resistance marker. A $p$-value $\leq 0.05$ was considered statistically significant.

**Results**

**Mutations in *pfdhfr* and *pfdhps* genes in isolates from the Thailand–Myanmar border**

A total of 146 *P. falciparum* samples collected from malaria clinics in five provinces between 2008 and 2016 were analysed (Table 1). The six point mutations of *pfdhfr* gene and five point mutations of *pfdhps* associated with resistance were assessed in all samples. Septuple mutations at N51I, C59R, S108N and I164L of *pfdhfr* with A437G, K450E and A581G of *pfdhps* presented as the main haplotype that was found in 51% (18/35), 50% (36/72) and 46% (18/39) from samples between 2008 and 2010, 2011–2013 and 2014–2016, respectively. The secondary group of the main haplotype became the main haplotype in the last period 2014–2016. Quintuple mutations (ACIRNI-A/SGKGA) increased from 8% (1/12) in 2008–2010 to 35% (20/57) in 2014–2016. Whereas, prevalence of falciparum parasite with quintuple mutations (ACIRNI-A/SGEAA) increased from 8% (1/12) in 2008–2010 to 18% (5/28) in 2014–2016 (Fig. 1). The multiple copy number of *pfghc1* gene were observed in 7% (2/28)–8% (1/12) in this region (Fig. 2).

**Mutations in *pfdhfr* and *pfdhps* genes in isolates from the Thailand–Cambodia border**

All 47 *P. falciparum* isolates from Yala province represented the samples from Thailand–Malaysia border (Table 1). All falciparum samples carried quadruple or quintuple mutation of *pfdhfr–pfdhps* gene. The major haplotype had mutations at N51I, C59R and S108N of *pfdhfr* and A437G of *pfdhps* that showed 67% (2/3) in 2008–2010, 100% (7/7) in 2011–2013 and 35% (13/37) in 2014–2016. Quintuple mutations (ACIRNI-A/SGEAA) decreased to 4% (1/28) in 2014–2016. Whereas, prevalence of falciparum parasite with quintuple mutations (ACIRNI-A/SGEAA) increased from 8% (1/12) in 2008–2010 to 18% (5/28) in 2014–2016 (Fig. 1). The multiple copy number of *pfghc1* gene amplification was found in 14% (5/37) of genes in 2014–2016 in contrast to absence of multiple copies in earlier samples (Fig. 2).

Comparing frequencies of mutations from three areas, prevalence of septuple (ACIRNL-A/SGEAA, ACNRNL-A/SGEAA and ACIRNI-A/SGEAA) were found in the falciparum samples from Thailand–Myanmar and Thailand–Cambodia border as the major group. Whereas, the falciparum samples of Thailand–Malaysia border presented only quintuple and quadruple mutations haplotypes. The octuple mutations which had the mutation at A/S436F or A613S/T were detected only in Thailand–Myanmar border. However, both of octuple haplotype observed below 8% in 2008–2013 were absent in 2014–2016 (Fig. 3).
Table 1  The *pfdhfr/pfdhps* haplotypes and *pfgh1* copy number variation of *P. falciparum* separated by Thailand-neighboring countries between 2008 and 2016

| Area                          | Year*  | DHFR A16V | C580R | NS11 | C59R | S108N | I164L | DHPS A5436F | A437G | KS40E/N | A581G | A6135/T | GCH1 Num. | Single/Multiple |
|------------------------------|--------|-----------|-------|------|------|-------|-------|-------------|-------|----------|--------|----------|-----------|-----------------|
| Thailand-Myanmar border      | 2008–2010 | A | C | N | N | R | N | L | A/S | G | E | A | A | S | 3 |
|                              |        | A | C | N | R | N | L | A/S | G | E | A | A | S | 1 |
|                              |        | A | C | I | R | N | I | A/S | G | E | A | A | M | 1 |
|                              |        | A | C | I | R | N | L | A/S | G | E | A | A | S | 4 |
|                              |        | A | C | I | R | N | L | A/S | G | E | A | A | A | 6 |
|                              |        | A | C | I | R | N | L | A/S | G | E | G | A | A | S | 12 |
|                              |        | A | C | I | R | N | L | A/S | G | E | G | A | A | M | 6 |
|                              |        | A | C | I | R | N | L | F | G | E | A | T | S | 2 |
|                              | 2011–2013 | A | C | N | R | N | I | A/S | G | E | G | A | M | 1 |
|                              |        | A | C | N | R | N | L | A/S | G | E | G | A | S | 1 |
|                              |        | A | C | I | R | N | I | A/S | G | E | A | A | S | 1 |
|                              |        | A | C | I | R | N | I | A/S | G | E | A | A | M | 1 |
|                              |        | A | C | I | R | N | I | A/S | G | E | G | A | S | 1 |
|                              |        | A | C | I | R | N | I | A/S | G | E | G | A | M | 5 |
|                              |        | A | C | I | R | N | I | A/S | G | K | A | A | S | 2 |
|                              |        | A | C | I | R | N | L | A/S | G | E | A | A | S | 11 |
|                              |        | A | C | I | R | N | L | A/S | G | E | A | A | M | 4 |
|                              |        | A | C | I | R | N | L | A/S | G | E | G | A | S | 19 |
|                              |        | A | C | I | R | N | L | A/S | G | E | G | A | M | 17 |
|                              |        | A | C | I | R | N | L | A/S | G | N | G | A | M | 1 |
|                              |        | A | C | I | R | N | L | F | G | E | A | T | S | 1 |
|                              |        | A | C | I | R | N | L | F | G | E | A | T | M | 1 |
|                              |        | A | C | I | R | N | L | F | G | E | G | A | S | 1 |
|                              |        | A | C | I | R | N | L | F | G | E | G | A | M | 5 |
|                              | 2014–2016 | A | C | I | R | N | I | A/S | G | E | A | A | S | 2 |
|                              |        | A | C | I | R | N | I | A/S | G | E | A | A | M | 1 |
|                              |        | A | C | I | R | N | I | A/S | G | K | A | A | S | 2 |
|                              |        | A | C | I | R | N | L | A/S | G | E | A | A | S | 4 |
|                              |        | A | C | I | R | N | L | A/S | G | E | A | A | M | 12 |
|                              |        | A | C | I | R | N | L | A/S | G | E | G | A | S | 5 |
|                              |        | A | C | I | R | N | L | A/S | G | E | G | A | M | 10 |
| Total                       |        | A | C | I | R | N | L | A/S | G | E | A | A | S | 146 |
Table 1 (continued)

| Area                               | Yeara   | DHFR       | DHP5       | GCH1       | Num. |
|------------------------------------|---------|------------|------------|------------|------|
|                                    |         | A16V | C50R | NS1I | C59R | S108N | I164L | A/S | A5436F | A437G | K540E/N | A581G | A613S7 | Single/Multiple |
| Thailand–Cambodia border           | 2008–2010 | A    | C    | I    | R    | N    | I     | A/S | G    | E    | A    | A    | S    | 1     |
|                                    |         | A    | C    | I    | R    | N    | I     | A/S | G    | N    | G    | A    | A    | S    | 2     |
|                                    |         | A    | C    | I    | R    | N    | L     | A/S | G    | E    | A    | A    | A    | M    | 1     |
|                                    |         | A    | C    | I    | R    | N    | L     | A/S | G    | N    | G    | A    | A    | S    | 6     |
|                                    | 2014–2016 | A    | C    | I    | R    | N    | I     | A/S | G    | E    | A    | A    | A    | S    | 5     |
|                                    |         | A    | C    | I    | R    | N    | I     | A/S | G    | K    | A    | A    | A    | S    | 1     |
|                                    |         | A    | C    | I    | R    | N    | I     | A/S | G    | K    | A    | A    | A    | M    | 1     |
|                                    |         | A    | C    | I    | R    | N    | L     | A/S | G    | E    | A    | A    | A    | S    | 1     |
|                                    |         | A    | C    | I    | R    | N    | L     | A/S | G    | N    | G    | A    | A    | S    | 19    |
|                                    |         | A    | C    | I    | R    | N    | L     | A/S | G    | N    | G    | A    | A    | M    | 1     |
| Total                             |         | A    | C    | I    | R    | N    | I     | A/S | G    | K    | A    | A    | S    | 2     |
|                                    |         | A    | C    | I    | R    | N    | L     | A/S | G    | K    | A    | A    | A    | S    | 1     |
|                                    | 2011–2013 | A    | C    | I    | R    | N    | I     | A/S | G    | K    | A    | A    | A    | S    | 7     |
|                                    | 2014–2016 | A    | C    | I    | R    | N    | I     | A/S | G    | K    | A    | A    | A    | S    | 13    |
|                                    |         | A    | C    | I    | R    | N    | I     | A/S | G    | K    | G    | A    | S    | 5     |
|                                    |         | A    | C    | I    | R    | N    | I     | A/S | G    | K    | G    | A    | S    | 19    |
| Total                             |         | A    | C    | I    | R    | N    | I     | A/S | G    | K    | G    | A    | S    | 47    |

Each italic upper script letters represent mutation observed in the amino acid at the corresponding position.

* The mutations observed are grouped based on year of sample collection.
Associations between *pfgch1* copy number and antifolate resistance markers in *pf dhfr* and *pf dhps*

The association between individual six mutation points in *pf dhfr* and gene amplification of *pfgch1* were assessed in all 233 samples. Only the I164L *pf dhfr* point mutation was significantly associated with *pfgch1* amplification ($\varphi = 0.213$, $p$-value $= 0.001$). *Plasmodium falciparum* carrying both the *pf dhfr* I164 allele and *pfgch1* multiple copies were observed in only 21% (15/73) of samples, while *P. falciparum* isolates that carried both *pf dhfr* 164L and *pfgch1* amplification were observed in 42% (67/160) of samples (Fig. 3).

Similarly, evaluation of the association between five mutation points in *pf dhps* and *pfgch1* gene amplification showed that the *pf dhps* K540E/N allele was significantly correlated to *pfgch1* amplification ($\varphi = 0.399$, $p$-value $\leq 0.001$). *Plasmodium falciparum* carrying the *pf dhps* 540E allele and *pfgch1* multiple copies was observed in 50% (75/151) of samples.

**Discussion**

This longitudinal study of antifolate resistance markers in Thailand *P. falciparum* infections showed persisting high prevalence of antifolate resistance haplotypes between 2008 and 2016, despite long-term cessation of SP treatment regimen. Studies from early 1990s to 2014, revealed the *pf dhfr* point mutations transitioning from double mutations (S108N with N511/C59R/164L, ≥ 72%) to triple (N51I, C59R, S108N or C59R, S108N, I164L) and eventually quadruple (N51I, C59R, S108N/T, I164L) mutations in provinces of Thailand bordering Myanmar and Cambodia [5, 10, 19–21]. Present findings are in agreement with previously observed trends showing that most *P. falciparum* parasites up to 75% carried triple or quadruple mutations in *pf dhfr*. However, limited data from 1994 to 1995 on the Thailand–Malaysia border indicated a high prevalence of 88% *pf dhfr* triple mutations, whereas no quadruple mutations were reported [22].

The *pf dhps* mutations based on four codons (S436F/A, A437G, A581G, and A613S/T) were first reported in mid 1990s along the Thailand–Myanmar border [5]. Multiple studies conducted between 2001 and 2007 collectively indicated fluctuating dominance of the *pf dhps* triple (2001–2003, > 95%), quadruple (2002–2003, > 67%) and triple (2004–2007, > 97%) mutations [9, 19, 23]. Taken together, previous reports [9, 10] and present findings indicate emerging trend in shift from *pf dhps* double to triple mutations as major mutant group along the Thailand–Myanmar and Thailand–Cambodia borders.

Resistance level to antifolate drug in falciparum malaria was increased and conferred by mutations in...
The combination of *pf*\textit{dhfr} N51I, C59R and S108N and *pf*\textit{dhps} A437G and K540E/N (quintuple mutant) strongly predicts clinical outcome \cite{24}. The mutation in *pf*\textit{dhfr} I164L and *pf*\textit{dhps} A581G and A613S/T developed later and were associated with increase in antifolate resistance \cite{6}.

**Fig. 2** The *pf*\textit{gch1} copy number variation in *P. falciparum* obtained from malaria patients between 2008 and 2016. (TH Thailand, MY Myanmar, CH Cambodia, ML Malaysia, MH Maehongson Province, TK Tak Province, KN Kanchanaburi Province, RN Ranong Province, ST Surathani Province, YL Yala Province, TR Trat Province, SK Srisaket Province, UB Ubonratchathani Province)

Effect of mutations in *pf*\textit{dhfr} on the inhibition constant ($K_I$) for pyrimethamine has been well described \cite{25–28}. This suggests that quadruple mutations including the 164 position were critically important for the development of resistance to pyrimethamine. In addition, it was shown that $K_I$ for sulfadoxine differed significantly between wild type and triple mutant parasites.
carrying K540E mutation [4, 29]. Strong association between elevated copy number of the pfgch1 gene and the pfdhfr-1164L mutation has been shown previously [8]. In this study, an association between pfgch1 gene multiple copy number and the pfdhfr-1164L mutation was also observed. However, in Ghana with low level of pfgch1 gene amplification (6%; 12/192), no dhfr-1164L was detected in samples with amplified pfgch1 [30]. The positive correlation between pfdhps (540E) and pfgch1 multiple copies observed in this study was not observed before. These correlations in parasites with high-level antifolate and anti-sulfonamide resistance may indicate functional linkage and fitness epistasis between genes on different chromosomes. The observed positive correlations between pfgch1 amplification and pfdhfr (1164L)/pfdhps (K540E/N) mutations may represent adaptation of the parasite dissociated from the antimalarial drug pressure or arguably the pressure from non-anti-malarial antifolate drugs.

Present study provides indication of co-increase in quintuple mutants and pfgch1 multiple copies in five isolates during 2014–2016. However, relatively smaller sample size (in total 37 isolates) from Thailand–Malaysia border might also have influenced the observed results. Persistence of high prevalence of antifolate resistance haplotypes in Thailand may be explained by several factors. Persistence of antifolate resistance markers might result from continued drug pressure from non-malarial antifolate drugs such as trimethoprim and sulfamethoxazole [11]. Trimethoprim–sulfamethoxazole (a.k.a Bactrim™) is still used in Thailand [31] as a part of standard package to care people with HIV/AIDS [32], urinary tract infection [33], melioidosis [34] and pneumonia [35]. The antifolate gene mutations might have been sustained because of continued presence of this antifolate drug pressure [11].

Human migration contributed to the spread of chloroquine resistant malaria from Southeast Asia to Africa during the 1970s, and SP resistance during the 1980s–1990s [36–38]. Studies conducted during 1998–2001 [39] and 2007–2009 [40], identified a high proportion of pfdhfr/pfdhps resistance haplotypes in parts of Myanmar sharing border regions with Thailand. This period coincided with the increased prevalence of pfdhfr/pfdhps mutants in Thailand [9, 19, 20]. The main haplotypes then were quadruple mutants for pfdhfr and triple mutants for pfdhps, respectively (Additional file 1: Table S2). The Thailand–Cambodia border showed a slight difference in the proportion of pfdhfr resistance haplotypes containing quadruple mutations, which was higher than the proportion of triple mutations observed between 2003 and 2007 [21], whereas the prevalence of pfdhps mutations was similar to Cambodia [20] (Additional file 1: Table S2). Present findings are in agreement with the low reported pfdhfr–pfdhps mutations on the Thailand–Malaysia border compared to other regions [9, 22]. It is likely that the parasite population in this border area, which is a conflict zone, is separate from the other border areas, with limited human migration carrying parasites between these areas.

Conclusions

Decades after cessation of SP as anti-malarial treatment in Thailand, there is a persistent high proportion of P. falciparum carrying both sulfadoxine and pyrimethamine resistance markers, with the exception of the Thailand–Malaysia border. Amplification of pfgch1 correlated with pfdhfr (1164L) and pfdhps (K540E) mutations, suggesting pfgch1 amplification might be compensatory to mutations in the pfdhfr and pfdhps genes.

Supplementary information

Supplementary information accompanies this paper at https://doi.org/10.1186/s12936-020-03176-x.

Additional file 1: Table S1. Primer and Probe sequences for detection of SP resistance markers in P. falciparum. Table S2. The prevalence reports of pfdhfr and pfdhps mutations close the border of Thailand and neighboring countries since 1990 to 2016. Table S3. The Pfdhfr/Pfdhps haplotypes and gch1 copy number variation of P. falciparum in 9 provinces along the border of Thailand-neighboring countries between 2008 and 2016.

Abbreviations

pfdhfr: Plasmodium falciparum dihydrofolate reductase; pfdhps: P. falciparum dihydropteroate synthase; pfgch1: P. falciparum GTP cyclohydrolase-1; SNPs: Single nucleotide polymorphisms; CNV: Copy number variation.

Acknowledgements

This study was supported by Thailand Science Research and Innovation (TSRI), RTA6280006 and Dean-MORU Scholarship, Faculty of Tropical Medicine, Mahidol University Thailand and the Wellcome Trust Mahidol University Oxford Tropical Medicine Research Programme.

Authors’ contributions

MI, NJD, AMD and PS designed the study. RS undertook the laboratory experiment. RS, PP, PS collected the samples. RS, KS, CK, and VM conducted data analysis. RS, VM, AMD and MI wrote the first draft. All authors read and approved the final manuscript.

Funding

This study was supported by Thailand Science Research and Innovation (TSRI), RTA6280006 and Dean-MORU Scholarship, Faculty of Tropical Medicine, Mahidol University Thailand and the Wellcome Trust Mahidol University Oxford Tropical Medicine Research Programme.

Availability of data and materials

The dataset generated during the current study are available from corresponding author on reasonable request.

Ethics approval and consent to participate

Ethical and Scientific procedure of this study were certificated by the ethics committee of the Faculty of Tropical Medicine, Mahidol University, Thailand. The sample materials used in this study were permitted by responsible person of the Antimalarial Drug Therapeutic Efficacy Monitoring Projects that were
References

1. WHO. Country cooperation strategy, Thailand. 2017–2021. Geneva: World Health Organization; 2017.

2. Harinasuta T, Suntharasamai P, Wravan C. Chloroquine-resistant falciparum malaria in Thailand. Lancet. 1965;2:657–60.

3. Wongsrichanalai C, Sirichaisinthop J, Kanwacki JJ, Congpuong K, Miller RS, Pang L, et al. Drug resistant malaria on the Thai-Myanmar and Thai-Cambodian borders. Southeast Asian J Trop Med Public Health. 2001;32:41–9.

4. Wang P, Read M, Sims PF, Hyde JE. Sulfadoxine resistance in the human malaria parasite Plasmodium falciparum is determined by mutations in dihydropteroate synthetase and an additional factor associated with folate utilization. Mol Microbiol. 1997;27:979–86.

5. Basco LK, Eldin de Pecoulas P, Wilson CM, Le Bras J, Mazabraud A. Point mutations in the dihydrofolate reductase-thymidylate synthase gene and pyrimethamine and cycloguanil resistance in Plasmodium falciparum. Mol Biochem Parasitol. 1992;52:149–57.

6. Cowman AF, Morry MJ, Biggs BA, Cross GA, Foote SJ. Amino acid changes in the dihydropteroate synthetase genes in Ghana. PLoS ONE. 2018;13:e0204871.

7. Heinberg A, Siu E, Stern C, Lawrence EA, Ferdig MT, Deitsch KW, et al. Plasmodium falciparum dhps and dhfr-ts mutations in the human malaria parasite Plasmodium falciparum is determined by copy number variation on the acrocentric chromosomes. Mol Microbiol. 2015;99:135–8.

8. Plowe CV, Cortese JF, Djdjme A, Nwanyanwu OC, Watkins WM, Winstanley AM. An outbreak of artemisinin resistant falciparum malaria in Eastern Thailand. Sci Rep. 2015;5:17412.

9. Nair S, Miller B, Barends M, Jaidee A, Patel J, Mayxay M, et al. Adaptation of Plasmodium falciparum to pyrimethamine in falciparum malaria. Proc Natl Acad Sci USA. 1994;91:7149–53.

10. Imwong M, Jindakhad T, Kunasol C, Sutawong K, Vejakama P, Dondorp AM. The genetic basis of artemisinin resistance in Plasmodium falciparum. Antimicrob Agents Chemother. 2011;55:155–64.

11. Peterson DS, Walliker D, Wellem TE. Evidence that a point mutation in the dihydropteroate synthetase gene of Plasmodium falciparum is linked to pyrimethamine resistance in the dihydrofolate reductase-thymidylate synthase gene of Plasmodium falciparum. Proc Natl Acad Sci USA. 1985;82:9114–8.

12. Sirawaraporn W, Sathitkul T, Sirawaraporn R, Yuthavong Y, Santi DV. Antifolate-resistant mutants of Plasmodium falciparum. Proc Natl Acad Sci USA. 1997;94:1124–9.

13. Kublin JG, Dzinjalalama FK, Kamwendo DD, Malik EM, Cortese JF, Martino LM, et al. Molecular markers for failure of sulfadoxine–pyrimethamine and chlorproguanil–dapsone treatment of Plasmodium falciparum malaria. J Infect Dis. 2002;185:380–8.

14. Cheyniom J, Kanchanakhan N, Vidyakada S, Harissutthanakorn P. Anti-malarial drug resistance mutation and proguanil susceptibility among African Plasmodium falciparum isolates in Thailand. J Infect Dis. 2005;191:3147–52.

15. Parola P, Pradines B, Simon F, Carlowitz MP, Minodier P, Ranjeva P, et al. Antimalarial drug susceptibility and point mutations associated with drug resistance in 248 Plasmodium falciparum isolates imported from Comoros to Marseille, France in 2004–2006. Antimicrob Agents Chemother. 2007;51:7431–7.

16. Tanomsing N, Imwong M, Pukrittayakamee S, Chotivanich K, Locareesawan S, Mayxay M, et al. Genetic analysis of the dihydrofolate reductase-thymidylate synthase gene from geographically diverse isolates of Plasmodium malariae. Antimicrob Agents Chemother. 2007;51:13525–30.

17. Vinayak S, Alam MT, Mloxson-Hayden T, McCollum AM, Sem R, Shah NK, et al. Origin and evolution of sulfadoxine-resistant Plasmodium falciparum. PLoS Pathog. 2010;6:e1000830.

18. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 2001;29:e45.

19. Kruyssood S, Imwong M, Wilaritama P, Pukrittayakamee S, Nonpraset A, Snuonou G, et al. Artesunate–dapsone–proguanil treatment of falciparum malaria: genotypic determinants of therapeutic response. Trans R Soc Trop Med Hyg. 2005;99:142–9.

20. Mita T, Tanabe K, Takahashi N, Tsukahara T, Eto H, Dysoley L, et al. Independent evolution of pyrimethamine resistance in Plasmodium falciparum isolates in Melanesia. Antimicrob Agents Chemother. 2007;51:1071–7.

21. Cheyniom J, Kanchanakhan N, Vidyakada S, Harissutthanakorn P. Anti-malarial drug resistance mutation and proguanil susceptibility among African Plasmodium falciparum isolates in Thailand. J Infect Dis. 2005;191:3147–52.

22. Cox-Singh J, Zakaia R, Abdullah MS, Rahman HA, Nagapan S, Singh B. Short report: differences in dihydrofolate reductase but not dihydropteroate synthetase alleles in Plasmodium falciparum isolates from geographically distinct areas in Malaysia. Am J Trop Med Hyg. 2001;64:28–31.

23. Mita T, Venkatesan M, Ohashi J, Cullen T, Takahashi N, Tsukahara T, et al. Limited geographical origin and global spread of sulfadoxine-resistant dhps alleles in Plasmodium falciparum populations. J Infect Dis. 2011;204:1980–8.

24. Kublin JG, Dzinjalalama FK, Kamwendo DD, Malik EM, Cortese JF, Martino LM, et al. Molecular markers for failure of sulfadoxine–pyrimethamine and chlorproguanil–dapsone treatment of Plasmodium falciparum malaria. J Infect Dis. 2002;185:380–8.

25. Cheyniom J, Kanchanakhan N, Vidyakada S, Harissutthanakorn P. Anti-malarial drug resistance mutation and proguanil susceptibility among African Plasmodium falciparum isolates in Thailand. J Infect Dis. 2005;191:3147–52.

26. Cowman AF, Morry MJ, Biggs BA, Cross GA, Foote SJ. Amino acid changes linked to pyrimethamine resistance in the dihydrofolate reductase-thymidylate synthase gene of Plasmodium falciparum. Proc Natl Acad Sci USA. 1988;85:9109–13.

27. Peterson DS, Walliker D, Wellem TE. Evidence that a point mutation in dihydrofolate reductase-thymidylate synthase confers resistance to pyrimethamine in falciparum malaria. Proc Natl Acad Sci USA. 1988;85:9114–8.

28. Thaithong S, Chan S-W, Songsomboon S, Wilairat P, SuesbILONg T, et al. Pyrimethamine resistance mutnts in Plasmodium falciparum. Mol Biochem Parasitol. 1992;52:149–57.

29. Triglia T, Cowman AF. Primary structure and expression of the dihydropterate synthetase gene of Plasmodium falciparum. Proc Natl Acad Sci USA. 1994;91:749–53.

30. Osei M, Arshad F, Matrevi SA, Asante KP, Awandare GA, Quashie NB, et al. Amplification of GTP-cyclohydrolase 1 gene in Plasmodium falciparum isolates with the quadruple mutant of dihydrofolate reductase and dihydropteroate synthase genes in Ghana. PLoS ONE. 2018;13:e0204871.

31. Sumpradit N, Suthajit S, Poonpolsub S, Chuanchuen R, Prakongsai P. Antifolate resistance mutation and proguanil susceptibility among African Plasmodium falciparum isolates in Thailand. Sci Rep. 2015;5:17412.

32. WHO. Guidelines on post-exposure prophylaxis for HIV and the use of co-trimoxazole prophylaxis for HIV-related infections among adults, adolescents and children. Geneva: World Health Organization; 2014.

33. Gunesyel O, Onur O, Erdeke M, Denizbas A. Trimethoprim/sulfamethoxazole resistance in urinary tract infections. J Emerg Med. 2009;36:338–41.

34. Cheyniom J, McBryde EJ, Wuthiekanun V, Chierakul W, Amornchai P, Day NP, et al. Dosing regimens of cotrimoxazole (trimethoprim-sulfamethoxazole) for meiosis. Antimicrob Agents Chemother. 2009;53:4193–9.
35. Calderón EJ, Gutiérrez-Rivero S, Durand-Joly I, Dei-Cas E. Pneumocystis infection in humans: diagnosis and treatment. Expert Rev Anti Infect Ther. 2010;8:683–701.
36. Anderson TJ, Roper C. The origins and spread of antimalarial drug resistance: lessons for policy makers. Acta Trop. 2005;94:269–80.
37. Naidoo I, Roper C. Following the path of most resistance: dhps K540E dispersal in African Plasmodium falciparum. Trends Parasitol. 2010;26:447–56.
38. Martens P, Hall L. Malaria on the move: human population movement and malaria transmission. Emerg Infect Dis. 2000;6:103–9.
39. Nair S, Brockman A, Paiphun L, Nosten F, Anderson TJ. Rapid genotyping of loci involved in antifolate drug resistance in Plasmodium falciparum by primer extension. Int J Parasitol. 2002;32:852–8.
40. Yang Z, Li C, Miao M, Zhang Z, Sun X, Meng H, et al. Multidrug-resistant genotypes of Plasmodium falciparum, Myanmar. Emerg Infect Dis. 2011;17:498–501.

**Publisher’s Note**
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.